Status:
WITHDRAWN
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
Lead Sponsor:
Epizyme, Inc.
Conditions:
Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
This trial will study how safely the tazemetostat works with other therapies in various hematological malignancies. Hematologic malignancies are cancers that most often begin in the bone marrow or lym...
Detailed Description
This phase 1b/2 trial studies how safely the EZH2 inhibitor tazemetostat works with other therapies in various hematological malignancies. Tazemetostat has been found to be a safe and effective drug t...
Eligibility Criteria
Inclusion
- Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 for Phase 1b and status 0 to 2 for Phase 2
- Must have documented relapsed, refractory, or progressive disease after 2 lines of treatment with systemic therapy
- Measurable disease
- Demonstrate adequate organ function
- Negative test results for acute or chronic hepatitis B virus (HBV) infection, hepatitis C virus (HCV) and human immunodeficiency virus
- No ongoing clinically significant reactions to prior anticancer treatments
- Willingness to follow pregnancy precautions and register into the mandatory REMS program in lenalidomide and pomalizdomide arms
Exclusion
- Presence or history of central nervous system involvement by lymphoma
- Less than minimum washout period of prior anticancer therapy as specified by the protocol
- Prior allogeneic haematopoietic stem cell transplantation
- History of solid organ transplant
- Major surgery within 4 weeks of the start of study drug.
- Significant cardiac or cardiovascular impairment as specified by protocol
- Venous thrombosis or pulmonary embolism within the last 3 months before starting tazemetostat
- History of any bleeding disorder, peptic ulcer disease, or significant bleeding within the last 1 month prior to enrollment
- Are unable to take oral medication OR have malabsorption syndrome or any other uncontrolled gastrointestinal condition
- Patients with known active infection, or reactivation of a latent infection, as specified by the protocol
- Known sensitivity or allergy to the study medications
- Unwilling to refrain from eating or drinking grapefruit juice, Seville oranges, and grapefruits while on study
- Prior exposure to tazemetostat
- Any condition that places the subject at unacceptable risk if he/she were to participate in the study or that confounds the ability to interpret data from the study.
- Prior history of myeloid malignancies or T-cell lymphoblastic lymphoma (T-LBL)/T-cell acute lymphoblastic leukemia (T-ALL)
- For patients with DLBCL in Arm 1 (tazemetostat plus tafasitamab plus lenalidomide) or Arm 2 (tazemetostat plus lenalidomide):
- \- Prior exposure to lenalidomide
- For patients with MCL in Arm 3 (tazemetostat plus acalabrutinib):
- Prior exposure to a BTKi
- Medical condition that would make treatment with a BTKi not reasonable (e.g. allergy to BTKi or mutations known not to respond to BTKi treatment or subjects unable to be transitioned off of proton pump inhibitors)
- For patients with MM in Arm 4:
- Prior exposure to pomalidomide
- Untreated or impending spinal cord compression in subjects
- For patients with FL in Arm 5:
- Grade 3b, mixed histology, or FL that has histologically transformed to DLBCL.
- History of significant neurological disorders, hemophagocytic lymphohistiocytosis (HLH), chronic active Epstein-Barr virus (EBV) infection, progressive multifocal leukoencephalopathy (PML), lung disease (ILD), drug-induced pneumonitis, autoimmune pneumonitis, and/or history of severe autoimmune disease
Key Trial Info
Start Date :
December 22 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 5 2023
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT05205252
Start Date
December 22 2021
End Date
July 5 2023
Last Update
August 15 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
California Cancer Associates For Research And Excellence, cCARE
Santa Fe, California, United States, 92024
2
Central Care Cancer Center
Bolivar, Missouri, United States, 65613
3
Astera Cancer Center
East Brunswick, New Jersey, United States, 08816